CNS=central nervous system; MDD=major depressive disorder.

References: 1. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63‑77. 2. Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017;16(7):472‑486. 3. Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate Jr CA. Glutamatergic neurotransmission: pathway to developing novel rapid‑acting antidepressant treatments. Int J Neuropsychopharmacol. 2019;22(2):119‑135. 4. Gasiorowska A, Wydrych M, Drapich P, et al. The biology and pathobiology of glutamatergic, cholinergic, and dopaminergic signaling in the aging brain. Front Aging Neurosci. 2021;13:654931. 5. Chinta SJ, Andersen JK. Dopaminergic neurons. Int J Biochem Cell Biol. 2005;37(5):942-946.

© 2025 Axsome Therapeutics, Inc. All rights reserved. PP-DEP-US-2500009 05/2025